Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259555 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
A Phase 3 study of Bipolar I Disorder and Manic Episode, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 322
- Enrollment target
- 20
- Study locations
NCT03259555 is a Phase 3 study of Bipolar I Disorder and Manic Episode that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 322 participants, roughly in line with the 318-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT03259555, a Phase 3 study of Bipolar I Disorder and Manic Episode, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 322 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brexpiprazole
Study Locations (20)
California
- ProScience Research Group - Culver City
- Collaborative Neuroscience Network, LLC - Garden Grove
- Behavioral Research Specialists, LLC - Glendale
- Pacific Research Partners, LLC - Oakland
- NRC Research Institute - Orange
- Asclepes Research Centers - Panorama City
- Ci Trials - Riverside
- Sharp Vista Hospital - San Diego
Florida
- Galiz Research - Hialeah
- Advanced Research Institute of Miami - Homestead
- Florida Behavioral Medicine - Largo
- Optimus U Corporation - Miami
- Behavioral Clinical Research, Inc. - North Miami
- Segal Trials - North Miami
Arkansas
- Woodland International Research Group - Little Rock
- Woodland Research Northwest, LLC - Rogers
Georgia
- Radiant Research Inc. - Atlanta
Illinois
- Alexian Brothers Center for Psychiatric Research - Hoffman Estates
Maryland
- CBH Health - Gaithersburg
Missouri
- Advanced Clinical Research Center, LLC - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2019-01-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259555
The ClinicalTrials.gov registry entry for NCT03259555 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 318-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bipolar I Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03259555 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03259555 about?
NCT03259555 is a clinical study titled "A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder". To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.
What is the current status of trial NCT03259555?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 322 participants. The study started on 2017-09-14. Estimated completion is 2019-01-02.
What conditions does trial NCT03259555 study?
This clinical trial studies the following conditions: Bipolar I Disorder, Manic Episode.
What interventions are being tested in trial NCT03259555?
The interventions under investigation include: Placebo (DRUG), Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT03259555?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03259555 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar I Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
COMPLETED · Phase 3
-
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
COMPLETED · Phase 3
-
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.